These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Circulating sRAGE in the diagnosis of osteolytic bone metastasis. Galliera E; Marazzi MG; Vianello E; Drago L; Luzzati A; Bendinelli P; Maroni P; Tacchini L; Desiderio MA; Corsi Romanelli MM J Biol Regul Homeost Agents; 2016; 30(4):1203-1208. PubMed ID: 28078875 [TBL] [Abstract][Full Text] [Related]
4. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients. Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760 [TBL] [Abstract][Full Text] [Related]
5. Vitamin E-stabilized UHMWPE: Biological response on human osteoblasts to wear debris. Galliera E; Ragone V; Marazzi MG; Selmin F; Banci L; Corsi Romanelli MM Clin Chim Acta; 2018 Nov; 486():18-25. PubMed ID: 30006289 [TBL] [Abstract][Full Text] [Related]
6. The role of Wnts in bone metastases. Hall CL; Keller ET Cancer Metastasis Rev; 2006 Dec; 25(4):551-8. PubMed ID: 17160558 [TBL] [Abstract][Full Text] [Related]
7. Role of Wnts in prostate cancer bone metastases. Hall CL; Kang S; MacDougald OA; Keller ET J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163 [TBL] [Abstract][Full Text] [Related]
8. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008 [TBL] [Abstract][Full Text] [Related]
9. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378 [TBL] [Abstract][Full Text] [Related]
10. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776 [TBL] [Abstract][Full Text] [Related]
11. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Taipaleenmäki H; Farina NH; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB Oncotarget; 2016 Nov; 7(48):79032-79046. PubMed ID: 27738322 [TBL] [Abstract][Full Text] [Related]
12. sCD14-ST and Related Osteoimmunological Biomarkers: A New Diagnostic Approach to Osteomyelitis. Galliera E; Massaccesi L; Suardi V; de Vecchi E; Villa F; Yi Z; Suo G; Lovati AB; Logoluso N; Corsi Romanelli MM; Pellegrini AV Diagnostics (Basel); 2024 Jul; 14(15):. PubMed ID: 39125464 [TBL] [Abstract][Full Text] [Related]
13. Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities. Li X; Yang J; Bao M; Zeng K; Fu S; Wang C; Ye L Life Sci; 2018 Sep; 208():33-45. PubMed ID: 29969609 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Canon J; Bryant R; Roudier M; Osgood T; Jones J; Miller R; Coxon A; Radinsky R; Dougall WC Bone; 2010 Jun; 46(6):1613-9. PubMed ID: 20215062 [TBL] [Abstract][Full Text] [Related]
15. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors. Taylan A; Birlik M; Kenar G; Toprak B; Gundogdu B; Gurler O; Karakas B; Akıncı B; Sisman AR Mod Rheumatol; 2019 Jul; 29(4):619-624. PubMed ID: 30001654 [No Abstract] [Full Text] [Related]
16. Paget's disease of bone: an osteoimmunological disorder? Numan MS; Amiable N; Brown JP; Michou L Drug Des Devel Ther; 2015; 9():4695-707. PubMed ID: 26316708 [TBL] [Abstract][Full Text] [Related]
17. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860 [TBL] [Abstract][Full Text] [Related]
18. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264 [TBL] [Abstract][Full Text] [Related]
19. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935 [TBL] [Abstract][Full Text] [Related]
20. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]